BRAF and colorectal carcinoma: Although Ciardiello et al. found no NLR association in RAS/BRAF mutant ctDNA patients [39], a much larger Italian study by Loupakis et al. identified NLR ≥ 3.0 as a prognostic marker for OS within the V600EBRAF-mutated subset of metastatic CRC patients, underlining its importance in this specific genetic context [40].